The HealthCare Institute of New Jersey (HINJ) supports responsible ways to lower health care costs for patients that do not jeopardize the ability of life sciences companies to research and discover the next generation of treatments and cures for patients everywhere.
We remain committed to working with all stakeholders to ensure that new barriers to patient access and the R&D process are not erected, especially as the life sciences work at breakneck speed to lead the world out of the COVID-19 pandemic.
In stark contrast, the White House Executive Order (EO) establishing a “most favored nation” policy toward health care costs threatens to disrupt patients’ ability to receive life-saving treatments, could significantly slow the pace of medical advancement, and seriously harm New Jersey’s workforce and economy.
Importing price controls from foreign countries endangers America’s role as a global medical innovation leader and imperils our nation’s ability to bring new medicines, diagnostic tools and medical technologies to market. We continue to maintain there are better ways than this onerous and ill-conceived plan to protect patient access and the innovation ecosystem upon which the world is relying to end this global crisis.